Select Publications
Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs 2007;18(1):7-15. Abstract
Fan F et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24(16):2647-53. Abstract
Fuchs C et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc ASCO 2006;Abstract 3506.
Goldberg RM et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12(1):38-50. Abstract
Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11(9):981-7. Abstract
Goldberg RM et al. The role of targeted therapy in the treatment of colorectal cancer. Clin Adv Hematol Oncol 2006;4(Suppl 17)(8):1-12. Abstract
Grothey A. Best of ASCO 2006: Colorectal cancer. Presentation. Beverly Hills, California. No abstract available
Haller DG et al. Tolerability of fluoropyrimidines appears to differ by region. Proc ASCO 2006;Abstract 3514.
Hochster HS et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Proc ASCO 2006;Abstract 3510.
Hoy SM, Wagstaff AJ. Panitumumab: In the treatment of metastatic colorectal cancer. Drugs2006;66(15):2005-14. Abstract
Lecomte T et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004;10(17):5880-8. Abstract
Lenz HJ. Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20(5 Suppl 2):5-13. Abstract
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33(4):369-85. Abstract
Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(2):118-24. Abstract
Saltz L et al. Panitumumab. Nat Rev Drug Discov 2006;5(12):987-8. No abstract available
Vallböhmer D et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005;23(15):3536-44. Abstract
Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11(9):1010-7. Abstract
Van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract
